Business Context and Reporting Period
Company: AnaptysBio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 9, 2026
Context: The filing announces the company's intent to disclose preliminary, unaudited financial information at the 2026 J.P. Morgan Healthcare Conference on January 11, 2026. The data pertains to the fiscal year ended December 31, 2025.
Key Financial Metrics
- Cash and Investments: Approximately $310 million as of December 31, 2025 (preliminary estimate).
- Revenue, Profit, and Margins: The filing text does not provide a clear value for revenue, net income, operating margins, or cash flow.
- Debt and Liquidity: Specific debt figures are not disclosed; liquidity is indicated by the cash position mentioned above.
Material Changes
The filing does not provide comparative data for the prior period to determine material changes in financial performance. It serves solely as a notice of upcoming preliminary disclosures.
Guidance, Outlook, and Risks
- Management Commentary: The company expects to present preliminary financial results at the upcoming conference.
- Risks and Contingencies: The preliminary financial information is an estimate subject to completion of financial closing procedures and audit adjustments. The filing explicitly states that these preliminary figures may differ materially from the actual results in the audited financial statements.
- Legal Status: The information in this Item 2.02 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings.
Investor Verification Checklist
- Verify the final audited financial statements for the fiscal year ended December 31, 2025, once released.
- Confirm the actual cash and cash equivalents balance against the preliminary $310 million estimate.
- Review the full corporate presentation (Exhibit 99.1) for additional operational updates not detailed in the 8-K summary.
- Monitor for any material adjustments resulting from the audit process that could alter the preliminary figures.